SNSE Sensei Biotherapeutics, Inc.

Price Chart

Executive Summary

Sensei Biotherapeutics filed an 8-K reporting the results of its June 10, 2026 annual meeting. Stockholders approved the 2026 Equity Incentive Plan (initial reserve of 2,671,981 shares plus up to 311,164 returning shares), the 2026 Employee Stock Purchase Plan (initial reserve of 267,198 shares), an amendment increasing authorized common shares from 12.5M to 300M, and the conversion of Series B Preferred into common stock. The filing is routine post-meeting disclosure with no material financial impact.

Actionable Insight

Key Facts

• Stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 2,671,981 shares plus up to 311,164 returning shares, with annual evergreen increases of 5% of outstanding shares through 2036.
• Stockholders approved the 2026 Employee Stock Purchase Plan with an initial reserve of 267,198 shares, with annual evergreen increases through 2036.
• Certificate of Incorporation amended to increase authorized common shares from 12,500,000 to 300,000,000.
• Stockholders approved the issuance of common shares upon conversion of Series B Non-Voting Convertible Preferred Stock, which will represent more than 20% of outstanding common shares and result in a change of control per Nasdaq rules.
• Directors Bob Holmen and Kristian Humer were elected with 741,993 and 741,275 votes for, respectively (311,652 broker non-votes).
• Deloitte & Touche LLP ratified as independent auditor for fiscal 2026 (1,055,703 for, 3,879 against, 17,592 abstained).

Financial Impact

Dilution from the Series B conversion is the primary financial impact. Prior DEFA14A indicated that conversion would add ~24.4M shares to the float (pro forma ~25.7M vs 1.3M actual shares outstanding). The new equity plans and authorized share increase enable future equity issuances but no immediate dilution beyond the Series B conversion.

Risk Factors

• Massive dilution from Series B preferred conversion (pro forma share count ~25.7M vs 1.3M actual, per prior DEFA14A).
• Additional dilution from 2026 equity plan shares (2.7M+ initial reserve plus evergreen 5% annual increases) and ESPP (267K+ initial reserve plus evergreen increases).
• Current $17M market cap with 1.3M shares outstanding — post-conversion value per share will be dramatically reduced.

Market Snapshot

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

US Market Status